ISSN: 2167-0846

Журнал боли и облегчения

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Индексировано в
  • Индекс Коперника
  • Google Scholar
  • Открыть J-ворота
  • Генамика ЖурналSeek
  • Космос ЕСЛИ
  • РефСик
  • Университет Хамдарда
  • ЭБСКО, Аризона
  • OCLC- WorldCat
  • Публикации
  • Женевский фонд медицинского образования и исследований
  • Евро Паб
  • ICMJE
Поделиться этой страницей

Абстрактный

Healthcare Resource Utilization And Costs Of Spinal Cord Injury With Neuropathic Pain In A Medicare Population

Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN and Nieshoff EC

Objective: Evaluation of healthcare resource utilization (HRU) and costs in patients with neuropathic pain (NeP) secondary to spinal cord injury (SCI) in a Medicare population.

Methods: Using data from the MarketScan Medicare Database between January 1, 2006 and June 30, 2011, patients with NeP following SCI (SCI-NeP cohort) were identified based on an ICD-9-CM diagnostic code indicative of SCI, and NeP (index event) within 12 months based on ICD-9-CM code 338.0x (central neuropathic pain) or a claim for an NeP-related antiepileptic or NeP-related antidepressant drug, and propensity score-matched to SCI patients without NeP (SCI-only). Pre-index demographic and clinical characteristics were compared between the cohorts. HRU and expenditures were compared for 12 months post-index. Generalized linear models and ordinary least squares models evaluated the association between characteristics and outcomes.

Results: The matched cohorts included 1,418 patients (approximately 54% male, mean age 77 years). During the 12-month follow-up period, SCI-NeP patients showed significantly greater use of evaluated medications (P < 0.01), and significantly higher HRU (P < 0.05), including 20% and 18% increased odds of hospitalization and emergency department visits, respectively. Mean (SD) total all-cause healthcare expenditures for this period adjusted for covariates showed an annual incremental economic burden of $6,808 (95% confidence interval $4,143, $9,764) per patient with NeP.

Conclusions: Medicare patients with NeP secondary to SCI have significantly higher HRU and costs relative to SCI patients without NeP. Medicare patients represent a population with special needs regarding therapeutic choices that may benefit from an integrated approach to NeP management.